S&P 500
(1.07%) 5 072.02 points
Dow Jones
(1.00%) 38 282 points
Nasdaq
(1.62%) 15 858 points
Oil
(0.18%) $79.14
Gas
(5.59%) $2.04
Gold
(0.25%) $2 316.80
Silver
(0.66%) $26.93
Platinum
(1.04%) $964.80
USD/EUR
(-0.09%) $0.932
USD/NOK
(-0.32%) $10.99
USD/GBP
(-0.09%) $0.798
USD/RUB
(-1.34%) $92.01

Actualizaciones en tiempo real para Keros Therapeutics Inc [KROS]

Bolsa: NASDAQ Sector: Healthcare Industria: Biotechnology
Upcoming Earnings Alert

Quarter results today
(bmo 2024-05-02)

Expected move: +/- 8.49%

BUY
100.00%
return 19.70%
SELL
33.33%
return 10.33%
Última actualización2 may 2024 @ 15:10

-0.33% $ 57.53

VENDER 112260 min ago

@ $58.15

Emitido: 14 feb 2024 @ 15:11


Retorno: -1.07%


Señal anterior: feb 13 - 09:30


Señal anterior: Comprar


Retorno: 4.68 %

Live Chart Being Loaded With Signals

Commentary (2 may 2024 @ 15:10):
Profile picture for Keros Therapeutics Inc

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need...

Stats
Volumen de hoy 146 350
Volumen promedio 361 314
Capitalización de mercado 2.07B
EPS $-1.340 ( 2024-03-01 )
Próxima fecha de ganancias ( $-1.350 ) 2024-05-30
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -11.06
ATR14 $0.0840 (0.15%)
Insider Trading
Date Person Action Amount type
2024-02-23 Seehra Jasbir Buy 125 000 Employee Stock Option (right to buy)
2024-02-13 Seehra Jasbir Buy 125 000 Employee Stock Option (right to buy)
2024-02-13 Regnante Keith Buy 40 000 Employee Stock Option (right to buy)
2024-02-13 Rovaldi Christopher Buy 150 000 Employee Stock Option (right to buy)
2024-02-13 Cooper Simon Peter Buy 40 000 Employee Stock Option (right to buy)
INSIDER POWER
67.74
Last 96 transactions
Buy: 1 546 013 | Sell: 365 314

Volumen Correlación

Largo: -0.04 (neutral)
Corto: -0.35 (neutral)
Signal:(50.412) Neutral

Keros Therapeutics Inc Correlación

10 Correlaciones Más Positivas
PRAX0.919
CDNA0.904
HNNA0.894
RPAY0.889
TTEC0.888
EWTX0.883
SMSI0.882
SRAX0.879
ANNX0.876
LPCN0.874
10 Correlaciones Más Negativas
CNST-0.811
UNCY-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Keros Therapeutics Inc Correlación - Moneda/Commodity

The country flag -0.31
( neutral )
The country flag -0.38
( neutral )
The country flag 0.00
( neutral )
The country flag -0.37
( neutral )
The country flag -0.18
( neutral )
The country flag 0.44
( neutral )

Keros Therapeutics Inc Finanzas

Annual 2023
Ingresos: $151 000
Beneficio Bruto: $-664 000 (-439.74 %)
EPS: $-5.20
FY 2023
Ingresos: $151 000
Beneficio Bruto: $-664 000 (-439.74 %)
EPS: $-5.20
FY 2022
Ingresos: $0
Beneficio Bruto: $-1.62M (0.00 %)
EPS: $-4.15
FY 2021
Ingresos: $20.10M
Beneficio Bruto: $0.00 (0.00 %)
EPS: $-2.52

Financial Reports:

No articles found.

Keros Therapeutics Inc

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico